11-01 :: December 2010 / January 2011
nanotimes
Companies Facts
The lithography equipment to be installed at CNF includes two specialized mask aligner toolsets for the SUSS MA/BA6 aligner: Substrate Conformal Imprin- ting Lithography (SCIL), a technology developed by SUSS MicroTec in conjunction with Philips Research, that provides an inexpensive means of defining features of 10nm or less with high reproducibility by using a full-size imprint stamp and MO Exposure Optics, a patented technique developed by SUSS MicroTec’s daughter company SUSS MicroOptics.
http://www.suss.com
http://www.cnf.cornell.edu
production solutions for the fabrication of advanced MEMS, power ICs and 3D ICs, launched the newest member of its popular ProNova™ family of high- density inductively coupled plasma (ICP) reactors for the company’s DRIE series wafer processing products.
A
The ProNova2™ is targeted for fast-growing 200-mm MEMS and 3D IC applications. It was built to out- perform the etch rates of comparative tools and deliver industry-leading DRIE productivity and yield benefits. In addition to demonstrating sustained high etch rates, the new reactor offers a three-fold impro- vement in ion uniformity. For some applications, the higher uniformity enables a 40-plus percent improve- ment in etch selectivity. The ProNova2™ also allows users to adjust selected etch parameters across the ICP reactor plasma and diffusion zones. This allows for better control of etch process performance across the wafer which boosts the silicon DRIE etch flexibili- ty needed for some advanced applications.
t SEMICON Japan, Tegal Corporation (NAS- DAQ: TGAL), an innovator of specialized
The first ProNova2™ tool has been installed in a Japanese development laboratory where it is meeting the performance expectations set by Tegal’s France- based R&D team.
http://www.Tegal.com
T
hermo Fisher Scientific Inc. (NYSE: TMO) has completed its previously announced acquisition
of Lomb Scientific, a well-known provider of labo- ratory chemicals, consumables and instruments in Australia and New Zealand.
Lomb Scientific has approximately 100 employees at its offices and warehouses in both countries, particu- larly in Sydney, Perth and Auckland. The company had full-year revenues of approximately AUD $34 million in 2009. Lomb Scientific will be integrated into both of Thermo Fisher Scientific’s business segments: Analytical Technologies and Laboratory Products and Services.
http://www.thermofisher.com
CHF7.8 million from new and existing investors. BB Biotech Ventures and Merck KGaA were joined by new investors Sunstone Capital, Merck Serono Ven- tures and BioMedPartners. The Company plans to use the proceeds of the financing to progress its lead program VXM01 into and through clinical phase I testing. VXM01 is an investigational oral T-cell vaccine that is designed to elicit an immune re- sponse against vascular endothelium growth factor receptor-2 (VEGFR-2), a well characterized target for anti-angiogenic intervention. VXM01 targets the tumor vasculature and has shown anti-tumor activity in a variety of animal studies testing different tumor
V
AXIMM AG, a Merck KGaA spin-off in Switzer- land, closed a private financing round totaling
39
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95